Stock Report

All about this stock under one free report Last Updated: 06-Sep-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Aerovate Therapeutics Inc (AVTE) Key Ratios

Stock Card factsheet share-fund-plan-icon

$2.68

up-down-arrow $-91.12 (-97.14%)

As on 28-Apr-2025 16:28EDT

Market cap

info icon

$78 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

35.6

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -- -- -- -- --
EBIT -- -- 43.46 -26.24 -282.79
Net Profit 53.63 89.14 40.43 -25.12 -280.03
EPS -- -- -- -- --
Book Value -- -- -- -- --
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-24Dec-23
EBIT-Margin info ----------
Net Margin info ----------
Return on equity info -57.77-19.15-62.96-74.91-63.95
Return on Capital info -57.40-15.23---74.48-63.47
Return on Assets info -52.56-80.57-35.32-67.03-57.49
Debt to Equity (x) info ----0.000.010.01

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Aerovate Therapeutics Inc (AVTE)
--
-74.48
-63.47
-34.25
-28.77
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-62.96

Lower than Peers by 22.56

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Aerovate Therapeutics Inc (AVTE)
-62.96
-74.91
-63.95
-34.44
-28.87
Peer Median
-40.40
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-35.32

Lower than Peers by 4.34

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Aerovate Therapeutics Inc (AVTE)
-35.32
-67.03
-57.49
-33.16
-25.50
Peer Median
-30.98
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

EBIT Growth

43.46

Higher than Peers by 44.26

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Aerovate Therapeutics Inc (AVTE)
43.46
8.37
-52.92
-131.24
-158.99
Peer Median
-0.80
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

40.43

Higher than Peers by 47.73

Year on year growth in profit after tax

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Aerovate Therapeutics Inc (AVTE)
40.43
7.80
-46.61
-124.32
-154.04
Peer Median
-7.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Aerovate Therapeutics Inc (AVTE)
--
0.01
0.01
0.01
0.00
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.00

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Aerovate Therapeutics Inc (AVTE)
0.00
0.01
0.00
0.01
0.00
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

32.01

Higher than Peers by 26.20

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Aerovate Therapeutics Inc (AVTE)
32.01
20.93
7.04
16.90
68.37
Peer Median
5.81
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

32.01

Higher than Peers by 26.32

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Aerovate Therapeutics Inc (AVTE)
32.01
--
--
--
--
Peer Median
5.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

--

--

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Aerovate Therapeutics Inc (AVTE)
--
--
--
-30.40
-354.18
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Asset Turnover

--

--

Sales / Average Total Assets

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Aerovate Therapeutics Inc (AVTE)
--
--
--
--
--
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Aerovate Therapeutics Inc (AVTE)
--
--
9,456.55
10,159.86
22,158.50
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Book Value

35.57

Higher than Peers by 30.39

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Aerovate Therapeutics Inc (AVTE)
35.57
--
--
--
--
Peer Median
5.18
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Aerovate Therapeutics Inc (AVTE)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

-9.33

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Aerovate Therapeutics Inc (AVTE)
-9.33
1.05
1.50
2.41
7.25
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

78

Lower than Peers by 68

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-24
Dec-23
Dec-22
Dec-21
Aerovate Therapeutics Inc (AVTE)
78
--
--
--
--
Peer Median
146
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...